Science 37, Otsuka Pharmaceutical Collaborate to Advance Digital Health Innovation

Science 37, a company focused on “site-less” clinical trials, and Otsuka Pharmaceutical Development & Commercialization, Inc., announced today a strategic collaboration to support efforts to further digitize Otsuka’s mobile clinical study protocols with a strong focus on psychiatry and behavioral health.

According to this morning’s official announcement, the collaboration follows an investment in Science 37 by Otsuka as a minority shareholder as part of the final close of a $35M Series C investment round earlier this year.

“Otsuka is dedicated to promoting innovation in clinical trials as a means of expanding the diversity of patients enrolled in studies, as well as bringing new products to market faster,” said William H. Carson, MD, president and CEO of Otsuka Pharmaceutical Development & Commercialization. “This collaboration with Science 37 is also the latest example of our commitment to leading in digital medicine and identifying new ways that technology can help transform the lives of patients.”

We’re told that the collaboration between the two companies will be conducted in successive phases and will develop effective ways to select, test, and manage innovative, patient-centric clinical studies to further the development of Otsuka products through a customized approach using the Science 37 platform.

“Our ecosystem of telemedicine technology, decentralized physician networks and in-house experienced clinical study staff has us uniquely positioned to take on new and exciting research studies,” said Noah Craft, MD, PhD, and co-founder and CEO of Science 37. “We always aim to align ourselves with companies who embrace ‘radical collaboration’ in science, so we are excited to collaborate with a company as committed to innovation in digital medicine as Otsuka.”

This post was written by:

- who has written 371 posts on mHealthWatch.

Contact the author